Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study
<p>Abstract</p> <p>Background</p> <p>Anti-TNF therapy has been shown to reduce radiographic joint damage in rheumatoid arthritis (RA) independent of clinical response. This has previously not been examined for periarticular bone loss, the other characteristic feature of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2011-02-01
|
| Series: | BMC Musculoskeletal Disorders |
| Online Access: | http://www.biomedcentral.com/1471-2474/12/54 |
| _version_ | 1818036844292472832 |
|---|---|
| author | Elden Aake Kälvesten Johan Kvien Tore K Hoff Mari Kavanaugh Arthur Haugeberg Glenn |
| author_facet | Elden Aake Kälvesten Johan Kvien Tore K Hoff Mari Kavanaugh Arthur Haugeberg Glenn |
| author_sort | Elden Aake |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Anti-TNF therapy has been shown to reduce radiographic joint damage in rheumatoid arthritis (RA) independent of clinical response. This has previously not been examined for periarticular bone loss, the other characteristic feature of bone involvement in RA.</p> <p>The objective of this study was to examine if treatment with the TNF-α inhibitor adalimumab also could reduce periarticular bone loss in RA patients independent of disease activity.</p> <p>Methods</p> <p>RA patients were recruited from the PREMIER study and included 214 patients treated with methotrexate (MTX) plus adalimumab and 188 patients treated with MTX monotherapy. Periarticular bone loss was assessed by digital X-ray radiogrammetry metacarpal cortical index (DXR-MCI). Change in DXR-MCI was evaluated in patients with different levels of clinical response, as assessed by changes in DAS28 score at 52 weeks and in mean C-reactive protein (CRP) levels during follow-up.</p> <p>Results</p> <p>In the MTX group, there was a greater median DXR-MCI loss among patients with moderate and high disease activity compared to those in remission or with low disease activity (-3.3% vs. -2.2%, p = 0.01). In contrast, periarticular bone loss was independent of disease activity (-1.9% vs. -2.4%, p = 0.99) in the combination group. In the MTX group patients with a mean CRP of ≥ 10 mg/l lost significantly more DXR-MCI than patients with low CRP (-3.1% vs. -1.9%, p <0.01) whereas in the combination group no significant differences between the two CRP groups was seen (-2.4% vs. -2.0%, p = 0.48).</p> <p>Conclusion</p> <p>Adalimumab in combination with MTX reduces periarticular bone loss independently of clinical response. These results support the hypothesis that TNF-α stimulates the osteoclast not only by the inflammatory pathway but do also have a direct effect on the osteoclast.</p> <p>Trial Registration</p> <p>ClinicalTrials (NCT): <a href="http://www.clinicaltrials.gov/ct2/show/NCT001195663">NCT001195663</a></p> |
| first_indexed | 2024-12-10T07:17:24Z |
| format | Article |
| id | doaj.art-ecf9dc4b1fbc435b8ec048fb6deed332 |
| institution | Directory Open Access Journal |
| issn | 1471-2474 |
| language | English |
| last_indexed | 2024-12-10T07:17:24Z |
| publishDate | 2011-02-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Musculoskeletal Disorders |
| spelling | doaj.art-ecf9dc4b1fbc435b8ec048fb6deed3322022-12-22T01:57:54ZengBMCBMC Musculoskeletal Disorders1471-24742011-02-011215410.1186/1471-2474-12-54Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER studyElden AakeKälvesten JohanKvien Tore KHoff MariKavanaugh ArthurHaugeberg Glenn<p>Abstract</p> <p>Background</p> <p>Anti-TNF therapy has been shown to reduce radiographic joint damage in rheumatoid arthritis (RA) independent of clinical response. This has previously not been examined for periarticular bone loss, the other characteristic feature of bone involvement in RA.</p> <p>The objective of this study was to examine if treatment with the TNF-α inhibitor adalimumab also could reduce periarticular bone loss in RA patients independent of disease activity.</p> <p>Methods</p> <p>RA patients were recruited from the PREMIER study and included 214 patients treated with methotrexate (MTX) plus adalimumab and 188 patients treated with MTX monotherapy. Periarticular bone loss was assessed by digital X-ray radiogrammetry metacarpal cortical index (DXR-MCI). Change in DXR-MCI was evaluated in patients with different levels of clinical response, as assessed by changes in DAS28 score at 52 weeks and in mean C-reactive protein (CRP) levels during follow-up.</p> <p>Results</p> <p>In the MTX group, there was a greater median DXR-MCI loss among patients with moderate and high disease activity compared to those in remission or with low disease activity (-3.3% vs. -2.2%, p = 0.01). In contrast, periarticular bone loss was independent of disease activity (-1.9% vs. -2.4%, p = 0.99) in the combination group. In the MTX group patients with a mean CRP of ≥ 10 mg/l lost significantly more DXR-MCI than patients with low CRP (-3.1% vs. -1.9%, p <0.01) whereas in the combination group no significant differences between the two CRP groups was seen (-2.4% vs. -2.0%, p = 0.48).</p> <p>Conclusion</p> <p>Adalimumab in combination with MTX reduces periarticular bone loss independently of clinical response. These results support the hypothesis that TNF-α stimulates the osteoclast not only by the inflammatory pathway but do also have a direct effect on the osteoclast.</p> <p>Trial Registration</p> <p>ClinicalTrials (NCT): <a href="http://www.clinicaltrials.gov/ct2/show/NCT001195663">NCT001195663</a></p>http://www.biomedcentral.com/1471-2474/12/54 |
| spellingShingle | Elden Aake Kälvesten Johan Kvien Tore K Hoff Mari Kavanaugh Arthur Haugeberg Glenn Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study BMC Musculoskeletal Disorders |
| title | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study |
| title_full | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study |
| title_fullStr | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study |
| title_full_unstemmed | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study |
| title_short | Adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response: Subanalysis of the PREMIER study |
| title_sort | adalimumab reduces hand bone loss in rheumatoid arthritis independent of clinical response subanalysis of the premier study |
| url | http://www.biomedcentral.com/1471-2474/12/54 |
| work_keys_str_mv | AT eldenaake adalimumabreduceshandbonelossinrheumatoidarthritisindependentofclinicalresponsesubanalysisofthepremierstudy AT kalvestenjohan adalimumabreduceshandbonelossinrheumatoidarthritisindependentofclinicalresponsesubanalysisofthepremierstudy AT kvientorek adalimumabreduceshandbonelossinrheumatoidarthritisindependentofclinicalresponsesubanalysisofthepremierstudy AT hoffmari adalimumabreduceshandbonelossinrheumatoidarthritisindependentofclinicalresponsesubanalysisofthepremierstudy AT kavanaugharthur adalimumabreduceshandbonelossinrheumatoidarthritisindependentofclinicalresponsesubanalysisofthepremierstudy AT haugebergglenn adalimumabreduceshandbonelossinrheumatoidarthritisindependentofclinicalresponsesubanalysisofthepremierstudy |